Loading
A phase 2 trial of Acasunlimab, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Genmab, stopped early.
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer is a phase 2 interventional study registered as NCT05117242 by Genmab, with 125 participants enrolled, started 2021-10-27 and reached its primary completion in 2024-12-02. Interventions recorded: Acasunlimab, Pembrolizumab. Conditions listed: Non Small Cell Lung Cancer Metastatic. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Acasunlimab, Genmab, Non-small-cell lung cancer.
Shares Genmab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Genmab, Small-cell lung cancer, Pembrolizumab, Non-small-cell lung cancer.
Shares Genmab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Genmab, Pembrolizumab, Non-small-cell lung cancer.
Shares Genmab, Pembrolizumab.
Shares Acasunlimab, Non-small-cell lung cancer.
Shares Genmab, Pembrolizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/